Evidence-based and patient-oriented inositol treatment in polycystic ovary syndrome: Changing the perspective of the disease

International Journal of Endocrinology and Metabolism

Volumn 15, Issue 1, 2017, Pages

  Laganà, Antonio Simone ^a   Rossetti, Paola ^b   Sapia, Fabrizio ^c   Chiofalo, Benito ^a   Buscema, Massimo ^b   Valenti, Gaetano ^c   Rapisarda, Agnese Maria Chiara ^c   Vitale, Salvatore Giovanni ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b Cannizzaro Emergency Hospital   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

Author keywords

Infertility; Inositol; Insulin Resistance; Polycystic Ovary Syndrome (PCOS)

Indexed keywords

DEXTRO DHIRO INOSITOL; INOSITOL; UNCLASSIFIED DRUG;

CLINICAL STUDY; DRUG EFFICACY; EDITORIAL; EVIDENCE BASED MEDICINE; HUMAN; MENSTRUAL CYCLE; META ANALYSIS (TOPIC); OVARY POLYCYSTIC DISEASE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

EID: 85012093072     PISSN: 1726913X     EISSN: 17269148     Source Type: Journal    
DOI: 10.5812/ijem.43695     Document Type: Editorial

References (10)

1. Laganà AS, Rossetti P, Buscema M, La Vignera S, Condorelli RA, Gullo G, et al. Metabolism and Ovarian Function in PCOSWomen: A Therapeutic Approach with Inositols. Int J Endocrinol. 2016;2016:6306410. doi: 10.1155/2016/6306410. [PubMed: 27579037].
2. Muscogiuri G, Palomba S, Laganà AS, Orio F. Current Insights about Inositol Isoforms, Mediterranean and Ketogenic Diets for Polycystic Ovary Syndrome: From Bench to Beside. Curr Pharm Des. 2016;22(36):5554-7. doi: 10.2174/1381612822666160720160634.
3. Vitale SG, Rossetti P, Corrado F, Rapisarda AM, La Vignera S, Condorelli RA, et al. How to Achieve High-Quality Oocytes? The Key Role of Myo-Inositol and Melatonin. Int J Endocrinol. 2016;2016:4987436. doi: 10.1155/2016/4987436. [PubMed: 27651794].
4. Paul C, Laganà AS, Maniglio P, Triolo O, Brady DM. Inositol's and other nutraceuticals' synergistic actions counteract insulin resistance in polycystic ovarian syndrome and metabolic syndrome: state-of-theart and future perspectives. Gynecol Endocrinol. 2016;32(6):431-8. doi: 10.3109/09513590.2016.1144741. [PubMed: 26927948].
5. Laganà AS, Barbaro L, Pizzo A. Evaluation of ovarian function and metabolic factors in women affected by polycystic ovary syndrome after treatment with D-Chiro-Inositol. Arch Gynecol Obstet. 2015;291(5):1181-6. doi: 10.1007/s00404-014-3552-6. [PubMed: 25416201].
6. Unfer V, Carlomagno G, Dante G, Facchinetti F. Effects of myoinositol in women with PCOS: a systematic review of randomized controlled trials. Gynecol Endocrinol. 2012;28(7):509-15. doi: 10.3109/09513590.2011.650660. [PubMed: 22296306].
7. Pizzo A, Laganà AS, Barbaro L. Comparison between effects of myoinositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS. Gynecol Endocrinol. 2014;30(3):205-8. doi: 10.3109/09513590.2013.860120. [PubMed: 24351072].
8. Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev. 2012(5):003053. doi: 10.1002/14651858.CD003053.pub5. [PubMed: 22592687].
9. Fruzzetti F, Perini D, Russo M, Bucci F, Gadducci A. Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS). Gynecol Endocrinol. 2016:1-4. doi: 10.1080/09513590.2016.1236078. [PubMed: 27808588].
10. Genazzani AD, Prati A, Santagni S, Ricchieri F, Chierchia E, Rattighieri E, et al. Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients. Gynecol Endocrinol. 2012;28(12):969-73. doi: 10.3109/09513590.2012.685205. [PubMed: 22612517].